Robert Louis Glanzman MD FAAN (He/Him)
Board certified neurologist, Fellow of the American Academy of Neurology, with extensive experience in neuroscience drug development and medical affairs.
Join to View Full Profile
123 East 2nd AvenueSalt Lake City, UT 84103
Phone+1 415-535-9032
Dr. Glanzman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a board certified neurologist and Fellow of the American Academy of Neurology. I have extensive experience in drug development and medical affairs for neuroscience-related disorders.
Education & Training
Duke University HospitalResidency, Nuclear Medicine, 1991 - 1992
University of MichiganResidency, Neurology, 1988 - 1991
Icahn School of Medicine at Mount Sinai (Cabrini)Internship, Internal Medicine, 1987 - 1988
Wake Forest School of Medicine of Wake Forest Baptist Medical CenterClass of 1987
Certifications & Licensure
UT State Medical License 2020 - 2026
NY State Medical License 2002 - 2021
MI State Medical License 1989 - 2002
NC State Medical License 1991 - 1998
American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Fellow American Academy of Neurology, 2020
Clinical Trials
Publications & Presentations
PubMed
- 2 citationsCNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial., James D Berry, Nicholas J Maragakis, Eric A Macklin, Lori B Chibnik
JAMA. 2025-02-17 - Correction: Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM- Au8, in the REPAIR phase 2 clin...Jimin Ren, Richard B Dewey 3rd, Austin Rynders, Jacob Evan, Jeremy Evan
Journal of Nanobiotechnology. 2024-01-03 - 10 citationsEvidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials.Jimin Ren, Richard B Dewey 3rd, Austin Rynders, Jacob Evan, Jeremy Evan
Journal of Nanobiotechnology. 2023-12-13
Journal Articles
- Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extensionSteve Vucic,a,∗ Parvathi Menon,a William Huynh,b Colin Mahoney,b Karen S. Ho,c Alan Hartford,c Austin Rynders,c Jacob Evan,c Jeremy Evan,c Shelia Ligozio,d Robert Glan..., eClinicalMedicine, 6/8/2023
Press Mentions
StockWatch: Despite Approval in ALS, Amylyx Sees No Price SurgeOctober 6th, 2022- Early CNM-Au8 Continues to Show Survival Benefits in ALS PatientsSeptember 27th, 2022
- Clene Nanomedicine Presents Updated Long-Term Survival Data from RESCUE-ALS Participants at 2022 AANEM Scientific ConferenceSeptember 21st, 2022
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
